← Eichor
Study identifier: NCT05599412 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Condition: Metastatic ALK+ Non Small Cell Lung Cancer  ·  Sponsor: Pfizer

PhaseN/A
Planned participants600
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (1)

PfizerSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05599412